Clarus Files for Chapter 11 Bankruptcy, Eyes Auction of Testosterone Therapy Jatenzo

Seeking AlphaSep 6, 2022 16:31

Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

GlobeNewswireSep 6, 2022 10:20

CLARUS THERAPEUTICS HLDGS INC C/WTS 11/08/2026 (TO PUR COM) | 8-K: Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

SECAug 19, 2022 04:14

CLARUS THERAPEUTICS HLDGS INC C/WTS 11/08/2026 (TO PUR COM) | 8-K: Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

SECMay 17, 2022 04:14

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

GlobeNewswireMay 12, 2022 21:10

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

GlobeNewswireMay 10, 2022 21:10